Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.68 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 7/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796712 | 1.00 | CYSLTR2 (0.68) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL8783516 | 0.84 | NPC1 (0.54) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL8783525 | 0.84 | NPC1 (0.54) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL8783716 | 0.84 | CYSLTR1 (0.54) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL8746348 | 0.84 | CYSLTR1 (0.54) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL8107515 | 0.83 | CYSLTR2 (0.70) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL8107518 | 0.83 | CYSLTR2 (0.70) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL1899506 | 0.82 | RAB9A (0.74) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL1899504 | 0.82 | RAB9A (0.74) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E | |
| SCHEMBL12884278 | 0.82 | RAB9A (0.73) | CYSLTR2CYSLTR1RAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0863876-B1 | QUINOLINE DERIVATIVES CONTAINING A DIOL AS LEUKOTRIENE ANTAGONISTS | LEO PHARM PROD LTD (DK) | 2002-01-30 | — | — | EP | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0863876-A1 | QUINOLINE DERIVATIVES CONTAINING A DIOL AS LEUKOTRIENE ANTAGONISTS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997019925-A9 | QUINOLINE DERIVATIVES CONTAINING A DIOL AS LEUKOTRIENE ANTAGONISTS | — | 1998-04-23 | — | — | WO | disclosed |
| WO-1997019925-A1 | QUINOLINE DERIVATIVES CONTAINING A DIOL AS LEUKOTRIENE ANTAGONISTS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1997-06-05 | — | — | WO | disclosed |
| EP-0773931-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1997-05-21 | — | — | EP | disclosed |
| US-5576438-A | LIPOXYGENASE INHIBITORS; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | Leo Pharmaceutical Products Ltd. A/S (L.o slashed.vens Kemiske Fabrik Produktionsaktiesel Skab) (DK) | 1996-11-19 | — | — | US | disclosed |
| WO-1996002506-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| EP-0654026-A1 | ISOSERINE DERIVATIVES AND THEIR USE AS LEUKOTRIENE ANTAGONISTS. | LEO PHARM PROD LTD (DK) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003431-A1 | ISOSERINE DERIVATIVES AND THEIR USE AS LEUKOTRIENE ANTAGONISTS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1994-02-17 | — | — | WO | disclosed |
| EP-0228959-B1 | AMINOSTYRYL COMPOUND, LEUKOTRIENE ANTAGONISTIC COMPOSITION CONTAINING THE SAME AS EFFECTIVE INGREDIENTS AND METHOD OF ANTAGONIZING SRS BY EMPLOYING THE SAME | MITSUBISHI KASEI CORPORATION (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4962203-A | ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROST CANADA, INC. (CA) | 1990-10-09 | — | — | US | disclosed |
| US-4749701-A | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1988-06-07 | — | — | US | disclosed |
| EP-0228959-A2 | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI KASEI CORPORATION (JP) | 1987-07-15 | — | — | EP | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | CYSLTR2 750/4885CYSLTR1 878/4885RAB9A 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.